小剂量米氮平联合度洛西汀治疗老年难治性抑郁症临床效果及安全性分析

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo investigate the clinical effect and safety of low dose Mirtazapine combined with Duloxetine in the treatment of senile refractory depression.Methods88 elderly patients with refractory depression in our hospital during the period from May 2015 to August 2016 were selected,and randomly divided into two groups according to the random number table method,the observation group (44 cases)and control group (44 cases).The control group were treated with Duloxetine treatment,the observation group were treated with small dose of Mirtazapine on the basis of control group,patients of two group were treated for two months.The scores of anxiety and depression,the clinical effect and adverse reactions were compared.ResultsThe scores of HAMA,HAMD and CGI-SI in the observation group were significantly lower than those in the control group after 2 weeks,5 weeks and 7 weeks,the difference was statistically significant(P<0.05).The TESS score of the observation group was(1.78±0.36)points,compared with the control group[(1.86±0.47)points],there was no statistically significant difference (P>0.05).The incidence of adverse reactions in observation group was 4.55%,compared with the control group 6.82%,showed no significant difference (P>0.05).The total effective rate in the observation group was 93.18%,significantly higher than the control group(72.72%),the difference was statistically significant(P<0.05).ConclusionFor elderly refractory depression patients,the combination of low-dose Mirtazapine and Duloxetine can achieve better therapeutic effect,and will not increase the incidence of adverse drug reactions.It is worth popularizing.

Key words： Mirtazapine Duloxetine Refractory depression Safety

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIANG Shen-hui
	YE Qing

Cite this article:

JIANG Shen-hui,YE Qing. Clinical effectand safety of low dose Mirtazapine combined with Duloxetine in the treatment of senile refractory depression[J]. 中国当代医药, 2017, 24(33): 75-77.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I33/75

[1]	孙虹，管锦群，王婷，等.度洛西汀治疗高龄帕金森病患者疼痛的疗效分析[J].中西医结合心脑血管病杂志，2015，15（4）：469-470.
[2]	欧灿纯，朱晓茜，朱金芳.度洛西汀、草酸艾司西酞普兰、米氮平治疗抑郁症的成本-效果分析[J].中国药师，2015，20（3）：449-451.
[3]	潘虹.文拉法辛和米氮平治疗难治性抑郁症的成本-效果对比研究[J].中国全科医学，2016，20（1）：338-339.
[4]	李涛，李刚，王莹.度洛西汀单用与合并认知行为治疗对产后抑郁症患者疗效的对照研究[J].临床精神医学杂志，2015，27（3）：188-190.
[5]	王玉文，宋明芬.度洛西汀与文拉法辛治疗抑郁症疗效和安全性的 Meta 分析[J].中国药师，2016，19（1）：96-99.
[6]	马元业，魏长礼，丁志杰.度洛西汀联合喹硫平治疗躯体化障碍的临床研究[J].国际精神病学杂志，2015，48（1）：14-16.
[7]	王文婷，仇福成，董慈，等.度洛西汀治疗体位性低血压伴焦虑抑郁的疗效观察[J].中西医结合心脑血管病杂志，2017，15（1）：21-25.
[8]	龚建兵，康延海，吴传东.疏肝解郁胶囊联合度洛西汀对抑郁症患者认知功能的影响[J].检验医学与临床，2016，13（24）：3539-3541.
[9]	李艳丽，谭云龙，李娟，等.盐酸度洛西汀肠溶片不同剂量滴定治疗抑郁症的多中心开放性研究[J].神经疾病与精神卫生，2015，15（6）：593-597.
[10]	潘江艳，杨盼，韦鑫，等.度洛西汀联合加巴喷丁治疗躯体形式疼痛障碍疗效分析[J].国际精神病学杂志，2017，48（1）：75-78.
[11]	孔杜娟，季凯.度洛西汀联合莫沙必利治疗功能性消化不良的疗效观察[J].医学综述，2015，24（21）：4001-4003.
[12]	王书田.度洛西汀与氟西汀治疗老年期抑郁症的比较观察[J].中国药物与临床，2015，17（6）：881-882.
[13]	钱烈，田国强，胡海芳，等.度洛西汀与氟西汀对照治疗脑卒中后抑郁的疗效观察[J].浙江医学，2016，38（12）：940-942.
[14]	岳莉莉，左文秀，汪辉耀，等.度洛西汀和米氮平治疗老年抑郁症的临床比较[J].国际精神病学杂志，2015，48（6）：37-40.
[15]	周磊，马蕊，张颖，等.度洛西汀联合小剂量奥氮平治疗伴有疼痛症状抑郁症的疗效[J].武警医学，2015，26（4）：364-366.